190 related articles for article (PubMed ID: 25010045)
1. Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
Hennigs JK; Müller J; Adam M; Spin JM; Riedel E; Graefen M; Bokemeyer C; Sauter G; Huland H; Schlomm T; Minner S
PLoS One; 2014; 9(7):e100469. PubMed ID: 25010045
[TBL] [Abstract][Full Text] [Related]
2. Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer.
Hennigs JK; Minner S; Tennstedt P; Löser R; Huland H; Klose H; Graefen M; Schlomm T; Sauter G; Bokemeyer C; Honecker F
Sci Rep; 2020 Feb; 10(1):3250. PubMed ID: 32094363
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
4. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A
Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694
[TBL] [Abstract][Full Text] [Related]
7. High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Grupp K; Sanader S; Sirma H; Simon R; Koop C; Prien K; Hube-Magg C; Salomon G; Graefen M; Heinzer H; Minner S; Izbicki JR; Sauter G; Schlomm T; Tsourlakis MC
Mol Oncol; 2013 Dec; 7(6):1001-11. PubMed ID: 23941784
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
[TBL] [Abstract][Full Text] [Related]
10. Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer.
Neubauer E; Latif M; Krause J; Heumann A; Armbrust M; Luehr C; Fraune C; Hube-Magg C; Kluth M; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe RS; Thederan I; Schlomm T; Büscheck F
Exp Mol Pathol; 2018 Aug; 105(1):50-56. PubMed ID: 29803408
[TBL] [Abstract][Full Text] [Related]
11. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
12. The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.
Büscheck F; Zub M; Heumann A; Hube-Magg C; Simon R; Lang DS; Höflmayer D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Sauter G; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Clauditz TS; Burandt E; Wilczak W; Steurer S; Minner S
Tumour Biol; 2019 Jul; 41(7):1010428318824815. PubMed ID: 31296150
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.
Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A
Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165
[TBL] [Abstract][Full Text] [Related]
16. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.
Qiu CZ; Wang C; Huang ZX; Zhu SZ; Wu YY; Qiu JL
World J Gastroenterol; 2006 Apr; 12(13):2011-5. PubMed ID: 16610049
[TBL] [Abstract][Full Text] [Related]
17. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
[TBL] [Abstract][Full Text] [Related]
18. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
[TBL] [Abstract][Full Text] [Related]
19. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
Halmos G; Schally AV; Sun B; Davis R; Bostwick DG; Plonowski A
J Clin Endocrinol Metab; 2000 Jul; 85(7):2564-71. PubMed ID: 10902809
[TBL] [Abstract][Full Text] [Related]
20. VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC; Khosrawi P; Weigand P; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Krech T; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S
Int J Mol Sci; 2015 Apr; 16(4):8591-606. PubMed ID: 25894226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
